DELIVER LONG-TERM CONTROL OF INFLAMMATION WITH RETISERT^®¹

Indication

RETISERT^® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

Important Safety Information

• Surgical placement of RETISERT^® (fluocinolone acetonide intravitreal implant) 0.59 mg is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.
• Based on clinical trials with RETISERT^®, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
• As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT^® into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.
• Following implantation of RETISERT^®, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
• Use of corticosteroids may result in elevated IOP and/or glaucoma. Based on clinical trials with RETISERT^®, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure.
• Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT^®. Physicians should periodically monitor the integrity of the implant by visual inspection.
• Ocular administration of corticosteroids has been associated with delayed wound healing and perforation of the globe where there is thinning of the sclera.
• The most frequently reported ocular adverse events in clinical trials with RETISERT^® occurring in 50-90% of patients included: cataract, increased intraocular pressure, procedural complications and eye pain. The most common non-ocular event reported was headache (33%).

Click here for full Prescribing Information for RETISERT^®.